anti-hypertensive sulfonanilide 1

Anti-hypertensive sulfonanilide 1 is an antihypertensive compound.

anti-TB agent 1 is a potent and orally active anti-tuberculosis agent (MICs: < 2 nM against the Mtb strains H37Rv, rRMP and rINH).

Anti-Inflammatory Peptide 1 Acetate (C45H82N12O14S2) possesses a potent anti-inflammatory activity in vivo and is a strong inhibitor of phospholipase A2 (PLA2), whose increased presence and activity results in inflammation and pain at certain bodily sites

RMP1-14 is an IgG1-like immunoglobulin and anti-Mouse PD-1 antibody that blocks PD-1/PD-L1 signaling.

Anti-MI/R injury agent 1 (compound 18), derived from Panaxatriol, represents an orally administered, potent agent against myocardial ischemia/reperfusion (MI/R) injury. It improves cell viability in cardiomyocytes subjected to oxygen-glucose deprivation and reperfusion (OGD/R)-induced injury. Furthermore, this compound significantly reduces myocardial infarction size, diminishes levels of circulating cardiac troponin I (cTnI), and mitigates cardiac tissue damage in rat models [1].

Anti-amyloid agent-1 is a potent compound that inhibits amyloid aggregation, offering a promising approach for research into the treatment of amyloidosis [1].

Anti-Trypanosoma cruzi agent-1 (Compd E5) has a potent anti-Toxoplasma effect.

Anti-neurodegeneration agent 1 a neurodegeneration-targeting agent.

Anti-MRSA agent 1 is an MRSA inhibitor with an MIC value of 0.5 μg/mL and is effective in alleviating the effects of MRSA resistance.

Anti-melanoma agent 1 (Compound 5m) is an anti-melanoma agent that induces apoptosis.

Anti-TSWV agent 1 is a highly effective inactivator (EC50:144 μg/mL) of tomato spotted wilt virus (TSWV).

Anti-osteoporosis agent-1 (comp 4aa) is an effective RPA (replication protein A) inhibitor, demonstrating potency with an IC50 value of 18 μM [1].

Anti-NASH Agent 1 (Compound 3d), derived from Elafibranor, serves as a strong PPAR-α/δ agonist aimed at treating nonalcoholic steatohepatitis (NASH). At dosages of 3-10 mg/kg over four weeks, this compound ameliorates hyperlipidemia, liver fat degeneration, and inflammation in a methionine-choline deficiency (MCD)-induced NASH mouse model, exhibiting minimal hepatotoxicity while providing substantial hepatic protection [1].

Anti-Heart Failure Agent 1 is an orally available compound suitable for the treatment of heart failure without inducing vomiting, nausea, and restlessness.

Anti-inflammatory agent 1 is an anti-inflammatory compound.

Anti-hyperglycemic agent 1 is a potent inhibitor of alpha-glucosidase (IC50: 0.53 μM). anti-Hyperglycemic agent 1 can be used to study diabetes.

Anti gram-positive/negative bacteria agent 1 is an antibiotic linked with a synthetic MECAM-based siderophore, serving as a conjugate aimed at combating gram-positive and gram-negative bacteria.

Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding to PD-1 and thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2).Sintilimab is used in combination with other compounds for the treatment of classical Hodgkin's lymphoma, non-cellular lung cancer and esophageal cancer. Sintilimab is used in combination with other compounds to treat classical Hodgkin's lymphoma, non-small cell lung cancer and esophageal cancer.

Anti-infective agent 1 (compound 3a) serves as a potent, selective antiprotozoal and antimycobacterial compound. It showcases antiparasitic efficacy against P. falciparum and T. brucei rhodesiense, demonstrating IC50 values of 10.95 and 0.06 μM, respectively. Moreover, it displays antimycobacterial properties against Mycobacterium smegmatis, exhibiting a minimum inhibitory concentration (MIC) of 8 μg/mL [1].

Anti-virus agent 1 (compound 4i), a phosphoramidate prodrug of GS-5734, exhibits potent antiviral efficacy. It is primarily utilized in the study of coronavirus and Ebola virus (EBOV).

Anti-IAV Agent 1-1a is an orally administered compound effective against the Influenza A virus (IAV), demonstrating inhibitory concentration 50 (IC50) values of 0.03 μM and 0.06 μM for the H1N1 strain and the Oseltamivir-resistant H1N1 strain of IAV, respectively.

anti-TNBC agent-1 is a highly effective compound specifically designed to target and combat triple-negative breast cancer (TNBC). It demonstrates remarkable potency against various breast cancer cell types, with IC50 values spanning from 0.20 μM to 0.27 μM. The mechanism of action of anti-TNBC agent-1 involves inducing apoptosis in SUM-159 cells through the mitochondria pathway, as well as causing G1 phase arrest in these cells.

Anti-neuroinflammation Agent 1 effectively modulates BV2 microglia cell polarization, shifting from an M1 to an M2 phenotype [1].

Anti-ToCV agent 1 can be used as a potential anti-ToCV drug.

Spartalizumab (anti-PD-1) is a useful organic compound for research related to life sciences and the catalog number is T35396.